Information Provided By: 
Fly News Breaks for March 28, 2016
BIIB
Mar 28, 2016 | 07:31 EDT
Leerink analyst Geoffrey Porges lowered his price target for Biogen to $328 after analyzing the company's opportunity in Spinal Muscular Atrophy. His updated revenue forecast for Nusinersen is "significantly later, and lower," than his prior forecast, driving down his price target for the shares. The analyst says that while Nusinersen Phase II studies in infants and children have yielded "promising" data to date, he keeps a "level of caution," particularly regarding the Type II/III studies. Porges keeps a Market Perform rating on Biogen.
News For BIIB From the Last 2 Days
BIIB
Apr 24, 2024 | 16:14 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
BIIB
Apr 24, 2024 | 13:04 EDT
BIIB
Apr 24, 2024 | 08:50 EDT
Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here
BIIB
Apr 24, 2024 | 06:50 EDT
BIIB
Apr 24, 2024 | 06:48 EDT
